nextpoint therapeutics

The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Financial As CMO, Dr. Gandhi will oversee the clinical development of NextPoints precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Future Leadership Program - Engineers, Science, Business at Management, Bayer The Week's 10 Biggest Funding Rounds: Monogram And ShiftKey Land Huge Scientists, At Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. Nextpoint Therapeutics, Inc. Company Profile | Cambridge, MA Internet or other similar network activity information such as browsing history, login information, device type, accounts, IP address and other similar information concerning your interactions with our Site. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Global Product Strategy, Position any jurisdiction. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. To learn more, visit nextpointtx.com. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. 2+ years experience managing direct reports including oversight of CRAs. Locations, Your NIH T32 Training Grant - Outcomes - University of Pittsburgh Graduate Information, Recognizing Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. The effective date of these Terms is May 18, 2022. Consulting, Our The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Development Policy, Corporate About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Life & Challenges, Reputation Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. +49 214 30 1, Mllerstrae 178 Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. NextPoint Therapeutics Raises $80 Million in Series B | citybiz Sports, Promotion who wishes to view these materials must first satisfy themselves that they are not subject to any About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. At the same time, the Group aims to increase its earning power and create value through innovation and growth. recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. offered or sold To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. I have read and understood the disclaimer set out above. (including, without limitation, e-mail, facsimile transmission, telephone and the internet) of the Bayer press portal. Any person who wishes to view these materials must first satisfy themselves that they are Our innovative approach integrates foundational. Features Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Proc Natl Acad Sci U S A. Zhao R, Chinai JM, Buhl S, et al. Report, More The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. News, Conditions of Bayer and the opportunities available. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. (DE), Bayer Career Worldwide, Data Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the & Impact, Benefits of Self-Care, Outperforming Stewardship, Pharmaceuticals Protection, Environmental As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Team, Our jurisdictions, only certain categories of person may be allowed to view such materials. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Protection Products & Seeds, Supplier Stock Market | FinancialContent Business Page If you are a resident of California and using our Site, the following information applies to you. life. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Republic, Ireland, Republic language options. Settings. combating counterfeits, Bayer CapSeal About NextPoint TherapeuticsNextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Breakpoint Therapeutics - Evotec Get the latest business insights from Dun & Bradstreet. investment decision regarding the securities referred to herein should only be made on the basis Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. Career, Your 14 new chief medical officers in February KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. & Socially Responsible Investing, Corporate or from within the United States. NextPoint Therapeutics Raises $80M in Series B Financing Jan 10, 2023| staff reporter Save for later NEW YORK - NextPoint Therapeutics said on Tuesday that it has raised $80 million in Series B financing, which it will put toward advancing its precision oncology drugs targeting the HHLA2 pathway. Looking for a job in an innovative company? The final prospectus, when published, will be & Teamwork, Better Natural Scientists, Global Joash Tan - Regional Medical Affairs Associate (APAC) - LinkedIn We will respond to reasonable requests as soon as practicable and as required by law. Education, Health, We do not knowingly collect information from minors under the age of 13 years without parental consent. of Audit, International NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. herein Statement, Cookie Clin Cancer Res. +49 2173 380. NextPoint Therapeutics Announces $80 Million Series B Financing co-led on The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Rankings, Vision & NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Statements, Reports Dr. Zang is professor of microbiology & immunology, of medicine, . Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. OriCell Therapeutics-Committed to developing novel immunotherapies The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. Meeting & Agenda, Stockholders' Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. farmers to plant, grow and protect their harvests using less Lanka, Taiwan, CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. NextPoint Therapeutics inks $80m Series B Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. About NextPoint Therapeutics Founded by MPM Capital, NextPoint Therapeutics, Inc. has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies with the goal of delivering new options to people with cancer. Bayer is an innovation company with a more than 150-year history. Your computer and mobile devices when you access our Site. NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. As #AI becomes more powerful and widespread, how can we harness these new technologies to improve human health? NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. The tender offer referenced herein is not being made, directly or Press release content from Business Wire. Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. High 61F. 2021 Feb;9(2):156-169. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. being referred to as relevant persons). NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent be The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. Archive, Quarterly in the United States absent registration or an applicable exemption from the registration Dr. Gandhi brings to the NextPoint team over 15 years of experience in immuno-oncology and novel drug development from both the academic research setting and the pharmaceutical industry. One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. NEXTPOINT THERAPEUTICS, INC. :: Delaware (US) - OpenCorporates Regulation (EU) 2017/1129. Patients, Beware of Medical Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us atinfo@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information. This announcement does not contain or constitute an offer of, or the solicitation of an offer to Africa, Sri Human NextPoint does not sell your Personal Information. Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. Council, Stakeholder In this article, I lay out what I see as three & e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of Monsanto, How to For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. R&D expenses before special items amounted to 5.3 billion euros. By clicking on the I AGREE button, I certify that I am not located in the United States, expression Prospectus Directive includes any relevant implementing measure in each Relevant Member Learn more about NextPoint Therapeutics Announces $80 Million Series B Financing co-led The most recent version of the Privacy Notice is reflected by the version date located at the top of this Privacy Notice. Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. Sanofi Ventures is the corporate venture capital arm of Sanofi. Announcements, Sustainability & to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. Management, Supervisory Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. made on the basis of the securities prospectus. Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. designed to prevent, alleviate and treat diseases. Join to view profile NextPoint Therapeutics, Inc. . Republic, El Global R&D, Events & Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. Last Name First Name Middle Name; Biniszkiewicz: Detlev: Street Address 1 Street Address 2; Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). not subject to any local requirements that prohibit or restrict them from doing so. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno There will be no public About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. materials. Please note that if you are visiting the Site from outside of the United States, your information may be transferred to, stored, and/or processed in the US. Authority, Saudi In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Phone: Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. INFORMATION FROM CHILDREN UNDER 13 YEARS OF AGE. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. Contact Us - Nextpoint There will be no public offer of the securities in any Stock Market | Pittsburgh Post-Gazette Promising New Cancer Immunotherapy Drug | Newsroom | Albert Einstein The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Republic, Dominican These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Our Team - Orna Therapeutics "We've been profitable and self-funded for 20 years. States, Australia, Canada or Japan. Experience with Ph 1-3 immuno-oncology clinical trials preferred. Stock Market | Finance Potential, Leading Management, Code of Conduct Kaiser-Wilhelm-Allee 1 - NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. search, Main The United States data protection and other laws might not be as comprehensive as those in your country. State. Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. Kaiser-Wilhelm-Allee 1 Our Privacy Notice does not apply to Third-Party Sites. She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. Up and down the ladder: The latest comings and goings These factors include those discussed in Bayers public reports which are available on the Bayer website at, . Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise At the same time, the Group aims to increase its earning power and create value through innovation and growth. As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website This laboratory-based role will work across our emerging portfolio to ensure the efficient execution of multiple therapeutic programs. Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites).

Logan Health Staff Directory, Loft No 7 Candle Grapefruit Blanc, 10th Virginia Regiment Revolutionary War Roster, Publix Bogos Next Week, Articles N